NO20055026L - Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse - Google Patents

Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse

Info

Publication number
NO20055026L
NO20055026L NO20055026A NO20055026A NO20055026L NO 20055026 L NO20055026 L NO 20055026L NO 20055026 A NO20055026 A NO 20055026A NO 20055026 A NO20055026 A NO 20055026A NO 20055026 L NO20055026 L NO 20055026L
Authority
NO
Norway
Prior art keywords
indolone
processes
preparation
acetamide derivatives
acetamide
Prior art date
Application number
NO20055026A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055026D0 (no
Inventor
Benoit Kenda
Jean-Philippe Starck
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO20055026D0 publication Critical patent/NO20055026D0/no
Publication of NO20055026L publication Critical patent/NO20055026L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20055026A 2003-03-31 2005-10-28 Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse NO20055026L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03007214 2003-03-31
PCT/EP2004/002691 WO2004087658A1 (en) 2003-03-31 2004-03-16 Indolone-acetamide derivatives, processes for preparing them and their uses

Publications (2)

Publication Number Publication Date
NO20055026D0 NO20055026D0 (no) 2005-10-28
NO20055026L true NO20055026L (no) 2005-12-22

Family

ID=33104041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055026A NO20055026L (no) 2003-03-31 2005-10-28 Indolonacetamid-derivater, fremgangsmate for fremstilling og anvendelse av disse

Country Status (18)

Country Link
US (2) US7645887B2 (de)
EP (1) EP1620399B1 (de)
JP (1) JP2006522041A (de)
KR (1) KR20050119186A (de)
CN (1) CN100364973C (de)
AR (1) AR043959A1 (de)
AT (1) ATE482193T1 (de)
AU (1) AU2004226288A1 (de)
BR (1) BRPI0408863A (de)
CA (1) CA2520568A1 (de)
DE (1) DE602004029245D1 (de)
ES (1) ES2353461T3 (de)
MX (1) MXPA05009089A (de)
NO (1) NO20055026L (de)
RU (1) RU2005131317A (de)
TW (1) TW200508197A (de)
WO (1) WO2004087658A1 (de)
ZA (1) ZA200507231B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
EP1719761A4 (de) * 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co Neue heterocyclische verbindung
AU2005263526A1 (en) 2004-07-22 2006-01-26 Ucb Pharma Sa Indolone derivatives, processes for preparing them and their uses
CA2604617C (en) 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
US8178533B2 (en) * 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
AR059265A1 (es) 2006-02-07 2008-03-19 Astrazeneca Ab Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)
US7875636B2 (en) * 2006-04-12 2011-01-25 Merck Sharp & Dohme Corp. Pyridyl amide T-type calcium channel antagonists
WO2008133933A1 (en) * 2007-04-26 2008-11-06 Trustees Of Columbia University In The City Of New York Methods, systems, and compositions for treating or ameliorating the effects of a non-congenital hypertonia
EP2152262A2 (de) * 2007-04-27 2010-02-17 UCB Pharma, S.A. Neue heterocyclische derivate zur behandlung von zns-erkrankungen
CA2702126A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
EP2346500B1 (de) 2008-10-16 2017-05-17 The Johns Hopkins University Verfahren und zusammensetzungen zur verbesserung der kognitiven funktion
EP2533645B1 (de) 2010-02-09 2016-07-27 The Johns Hopkins University Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
CN107540597A (zh) * 2017-09-22 2018-01-05 苏州大学 N‑乙酰二甲胺基吲哚‑2‑酮衍生物的制备方法
US20210214359A1 (en) * 2018-05-29 2021-07-15 New York University Compounds and Methods for Treating Bacterial Infections
KR102669101B1 (ko) * 2021-08-10 2024-05-27 충북대학교 산학협력단 신규한 옥소인돌린 기반 아세토히드라지드 및 이를 유효성분으로 포함하는 항암제 조성물
CN114874127B (zh) * 2022-05-23 2023-06-09 中国药科大学 一种二氟羰基化吲哚酮类化合物的制备方法
EP4572852A1 (de) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepinderivate, zusammensetzungen und verfahren zur behandlung von kognitiver beeinträchtigung

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064910D1 (en) 1979-06-12 1983-10-27 Fujisawa Pharmaceutical Co 2-oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives
JPS5697268A (en) * 1979-12-28 1981-08-05 Fujisawa Pharmaceut Co Ltd Lower alkanoic acid derivative, salt and preparation thereof and preventing agent and remedy for diabetic complication containing the same as active constituent
SU841264A1 (ru) 1980-02-20 1995-11-10 Научно-исследовательский институт фармакологии АМН СССР Амид-2-оксо-1-индолинуксусной кислоты, обладающий противосудорожной активностью
DE3413572A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Oxindol-verbindungen zur behandlung der epilepsie
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
DK288287A (da) * 1986-06-09 1987-12-10 Pfizer Heterocycliske forbindelser samt farmaceutiske praeparater til behandling af allergiske eller inflammatoriske tilstande
JPH0195766A (ja) 1987-10-08 1989-04-13 Tamanoisu Kk 無蒸煮アルコール醪からの食酢の製造法
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
CA2036307C (en) 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
BR9200951A (pt) * 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
JPH07304736A (ja) * 1994-05-10 1995-11-21 Kyowa Hakko Kogyo Co Ltd インドール誘導体
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
FR2738818B1 (fr) * 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
EP0960102A1 (de) * 1996-07-08 1999-12-01 Du Pont Pharmaceuticals Company Amidinoindole, amidinoazole und analoge davon als inhibitoren von thrombin und von faktor xa
JPH1095766A (ja) * 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US20020045566A1 (en) * 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
JP4673294B2 (ja) * 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
AU2005263526A1 (en) 2004-07-22 2006-01-26 Ucb Pharma Sa Indolone derivatives, processes for preparing them and their uses

Also Published As

Publication number Publication date
AU2004226288A1 (en) 2004-10-14
WO2004087658A1 (en) 2004-10-14
MXPA05009089A (es) 2005-11-17
TW200508197A (en) 2005-03-01
NO20055026D0 (no) 2005-10-28
EP1620399A1 (de) 2006-02-01
BRPI0408863A (pt) 2006-04-11
US7964593B2 (en) 2011-06-21
RU2005131317A (ru) 2006-02-27
KR20050119186A (ko) 2005-12-20
US20070043038A1 (en) 2007-02-22
EP1620399B1 (de) 2010-09-22
CN1768036A (zh) 2006-05-03
US20100069375A1 (en) 2010-03-18
HK1089768A1 (zh) 2006-12-08
US7645887B2 (en) 2010-01-12
ZA200507231B (en) 2006-11-29
AR043959A1 (es) 2005-08-17
CA2520568A1 (en) 2004-10-14
JP2006522041A (ja) 2006-09-28
ES2353461T3 (es) 2011-03-02
ATE482193T1 (de) 2010-10-15
DE602004029245D1 (de) 2010-11-04
CN100364973C (zh) 2008-01-30

Similar Documents

Publication Publication Date Title
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
SG161310A1 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
DE602004014361D1 (de) Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen
EA201170571A1 (ru) Способы и композиции для улучшения когнитивной функции
SE0301700D0 (sv) Novel compounds
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EA201070247A1 (ru) Ингибиторы протеасом
ATE433447T1 (de) Pyrimiidinverbindungen
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200738659A (en) Novel compounds
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DK1608655T3 (da) Pyrroloimidazolderivater, fremstillingen deraf, farmaceutiske præparater indeholdende disse og anvendelse deraf som nootrope midler
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application